We protect your health through science
Investigation
Measles, rubella, mumps, parvovirus B19 and rabies
Research Lines
Content with Investigacion .
Mechanisms of pathogenic fungal host adaptation: Morphogenesis in Cryptococcus neoformans
One of the main mechanisms by which fungi are able to cause disease in humans is their ability to evade the immune response and adapt to the environmental conditions found in the host. In this regard, one of the yeasts that has the greatest ability to adapt to the host is Cryptococcus neoformans. This fungus is found in the environment, and is acquired by inhalation, although the most typical picture is meningitis in immunocompromised patients, mainly HIV+. The main phenotypic characteristic is the presence of a polysaccharide capsule surrounding the cell, which is considered a virulence factor. In addition, C. neoformans is able to increase cell size significantly forming “titan” cells, which can reach a diameter of more than 70 microns. In the laboratory, we are interested in the role of these titan cells in the virulence of C. neoformans. Recently, we have described in vitro media in which C. neoformans forms pseudo-titan cells, which has allowed us to identify new factors and pathways involved in this process.
Mechanisms of action of antifungals
In parallel, we have a line whose main objective is to characterize the mechanisms of action of antifungals. Specifically, we have focused our work on the effect of Amphotericin B (AmB). For decades it has been thought that this antifungal causes cell death after binding to ergosterol and pore formation. Our results indicate that this antifungal also induces strong oxidative stress in the cell, which occurs before cell integrity is lost. Furthermore, we have shown that oxidative stress is necessary for the fungicidal action of AmB. These results open the door to design new strategies to improve its efficiency in patients.
New therapeutic strategies
Work with AmB has led to research aimed at improving antifungal therapies. In particular, we have used the strategy of “off-patent” drug repositioning to search for new activities. Using this approach, we have identified several drugs that increase the effectiveness of AmB against major pathogenic yeasts, such as the antibiotic erythromycin. This approach has allowed us to identify drugs with antifungal activity against emerging pathogens, such as Candida auris.
Research projects
Content with Investigacion .
Projects with public funding
TITLE: Virulence factors of pathogenic yeasts and their influence on the host.
FUNDING ENTITY: Ministry of Education and Science.
POSITION HELD: Principal Investigator, Contracted “Ramón y Cajal”.
START/FINISH: 2006-2007
AMOUNT: 15,000 EUROS
TITLE: Characterization of fungal giant cells and their role during infection in mammals.
FINANCING ENTITY: Instituto de Salud Carlos III
POSITION HELD: Principal Investigator, Contracted “Ramón y Cajal”.
START/FINISH: 2006-2007
AMOUNT: 55,000 EUROS
TITLE: Search and identification of genes involved in the resistance to antifungal agents in
Cryptococcus neoformans
FUNDING ENTITY: Ministry of Science and Innovation.
POSITION HELD: Principal Investigator, Contracted “Ramón y Cajal”.
START/FINISH: 2008-2010
AMOUNT: 25,000 EUROS
COLLABORATORS: Juan Luis Rodríguez Tudela (National Center of Microbiology, ISCIII. Madrid); Manuel Cuenca Estrella (National Center of Microbiology, ISCIII. Madrid); Maria Jose Gianinni (Faculdade de Ciências Farmacêuticas-UNESP). Brazil
TITLE: Role of morphological changes of the pathogenic yeast Cryptococcus neoformans during host infection.
FUNDING ENTITY: Ministry of Science and Innovation. National Plan Program “Non-oriented Fundamental Research”, area of Biomedicine, SAF2008-03761.
POSITION HELD: Principal Investigator, Contracted “Ramón y Cajal”.
START/END: 2009-2011
AMOUNT: 46,000 EUROS
PROJECT TITLE: Identification of the molecular mechanisms involved in the morphogenesis of Cryptococcus neoformans and study of their function during infection.
FUNDING ENTITY: Ministry of Science and Innovation, National Plan for Non-Oriented Fundamental Research, Biomedicine Area, Referencia: SAF2011-25140
DURATION FROM: January 2012 UNTIL: December 2014
PRINCIPAL INVESTIGATOR: Oscar Zaragoza Hernández
This project has an FPI grantee granted.
SUBSIDY: 90.000 euros
TITLE: Importance of morphogenesis in the virulence of pathogenic yeast Cryptococcus neoformans and improvement of amphotericin B-based cryptococcosis therapy. Reference: SAF2014-25140
FUNDING ENTITY: MINECO (Call for R+D+I Projects “RETOS INVESTIGACION)
POSITION HELD: Principal Investigator
START/FINISH: 2015-2017
Funding: 100.000 €.
TITLE: Study of the molecular basis and factors inducing morphological changes in Cryptococcus neoformans and characterization of new therapeutic strategies. Reference: SAF2017-86912-R
FUNDING ENTITY: MINECO (Call for R+D+I Projects “RETOS INVESTIGACION)
POSITION HELD: Principal Investigator
START/END: 2018-2020
Funding: 106.000 €.
TITLE: Mechanisms of adaptation of the pathogenic yeast Cryptococcus neoformans to the lung. Reference: PID2020-114546RB
FUNDING ENTITY: Ministry of Science and Innovation, State Research Agency (Call “Proyectos I+D+I” 2020 - Modalities “Research Challenges” and “Knowledge Generation”).
POSITION HELD: Principal Researcher
START/END: 01/09/2021-31/05/2025
Funding: 143,990 €.
TITLE: Precision medicine against antimicrobial resistance. MePRAM Project.
FUNDING ENTITY: Research Projects on Precision Personalized Medicine of the Strategic Action in Health 2021-2023, under the PERTE for Vanguard Health and charged to the European funds of the Recovery, Transformation and Resilience Plan.
POSITION: Collaborator (Principal Investigator: Jesús Oteo Iglesias)
START/FINISH: 2023-2025
Funding: 4.339.500 €.
TITLE: Centre for Biomedical Research in Network. Infectious Diseases Area (CIBERINFEC)
Funding Agency: Insituto de Salud Carlos III. Reference: CB21/13/00105
Dates: 2022-2026 Funding: 85.000 € (first year)
PI: Emilia Mellado Terrado / CoPI: Óscar Zaragoza Hernández
TITLE: Study of the genetic, metabolic and cellular determinants that influence titan cell formation in the fungal pathogen Cryptococcus neoformans and correlation with antifungal exposure.
CALL FOR PROJECTS: Knowledge Generation Projects.
FUNDING ENTITY. State Research Agency. Ministry of Science, Innovation and Universities.
REFERENCE: Project PID2023-148686OB-I00 Project funded by MICIU/AEI/10.13039/501100011033 and by FEDER, EU.
PRINCIPAL INVESTIGATOR: Oscar Zaragoza Hernández
START/END: 2024-2027
FUNDING: 180.000 €.
TITLE: Characterization of azole-resistant Candida parapsilosis isolates associated with hospital outbreaks: New strategies for their detection and treatment.
CALL: Strategic Action in Intramural Health.
FUNDING ENTITY. Carlos III Health Institute.
REFERENCE: AESI-2024 PI24CIII/00051
PRINCIPAL RESEARCHER: Oscar Zaragoza Hernández / Laura Alcázar Fuoli
START/FINISH: /01/012025-31/12/2027
FUNDING: 70.000 €.
Projects financed by biotechnology companies
PROJECT TITLE: Amphores. Evaluation of the induction of oxidative damage by Amphoterin B in susceptible and resistant yeast species.
FUNDING ENTITY: Gilead
DURATION FROM: 2011 TO: 2012
PRINCIPAL INVESTIGATOR: Oscar Zaragoza Hernández
GRANT: 55,000 euros
TITLE: Fungomics. Evaluation of the activity of amphotericin B and other antifungals against human pathogenic fungi.
FINANCING ENTITY: Gilead
POSITION HELD: Principal Investigator
START/END: 2019-2020
TITLE: Antifungal susceptibility testing of a set of Candida spp to CD101 and anidulafungin in five microdilution plates.
FUNDING ENTITY: Cidara
POSITION HELD: Principal Investigator
START/END: 2018
TITLE: Cidara MultiCentre EUCAST study
FUNDING ENTITY: Cidara
POSITION HELD: Principal Investigator
START/END: 2016
TITLE: Characterization of triazole-resistant Candida parapsilosis isolates from Spanish hospitals
FUNDING ENTITY: Gilead Science
POSITION HELD: Principal Investigator
START/END: 2022-2023
TITLE: EUCAST multicentre MIC testing of manogepix meeting EUCAST ECOFF setting criteria
FUNDING ENTITY: Pfizer
POSITION HELD: Principal Investigator
START/END: 2023
Publications
Hypervirulent Klebsiella pneumoniae: Epidemiology outside Asian countries, antibiotic resistance association, methods of detection and clinical management
12. Hypervirulent Klebsiella pneumoniae: Epidemiology outside Asian countries, antibiotic resistance association, methods of detection and clinical management. Autores: García-Cobos S, Oteo-Iglesias J, Pérez-Vázquez M. Revista: Enferm Infecc Microbiol Clin (Engl Ed). 2025 Feb;43(2):102-109.
PUBMED DOIPodocytes as new cellular targets of hemoglobin toxicity in massive intravascular hemolysis.
Rubio-Navarro A, Sanchez-Niño MD, Guerrero-Hue M, García-Caballero C, Gutiérrez E, Yuste C, Sevillano A, Praga M, Egea J, Román E, Cannata P, Ortega R, Cortegano I, de Andrés B, Gaspar ML, Cadenas S, Ortiz A, Egido J, Moreno JA. Podocytes as new cellular targets of hemoglobin toxicity in massive intravascular hemolysis. 2018. J.Pathol. 244(3):296-310.
PUBMED DOICarbapenemase-Producing Klebsiella pneumoniae in COVID-19 Intensive Care Patients: Identification of IncL-VIM-1 Plasmid in Previously Non-Predominant Sequence Types.
13. Carbapenemase-Producing Klebsiella pneumoniae in COVID-19 Intensive Care Patients: Identification of IncL-VIM-1 Plasmid in Previously Non-Predominant Sequence Types. Autores: Cañada-García JE, Ramírez de Arellano E, Jiménez-Orellana M, Viedma E, Sánchez A, Alhambra A, Villa J, Delgado-Iribarren A, Bautista V, Lara N, García-Cobos S, Aracil B, Cercenado E, Pérez-Vázquez M, Oteo-Iglesias J. Revista: Antibiotics (Basel). 2023 Jan 6;12(1):107.
PUBMED DOIPertactin-Deficient Bordetella pertussis with Unusual Mechanism of Pertactin Disruption, Spain, 1986-2018
14. Mir-Cros A, Moreno-Mingorance A, Martín-Gómez MT, Abad R, Bloise I, Campins M, González-Praetorius A, Gutiérrez MN, Martín-González H, Muñoz-Almagro C, Orellana MÁ, de Pablos M, Roca-Grande J, Rodrigo C, Rodríguez ME, Uriona S, Vidal MJ, Pumarola T, Larrosa MN, González-López JJ. Emerg Infect Dis. 2022 May;28(5):967-976
PUBMED DOIGenomic Background and Phylogeny of cfiA-Positive Bacteroides fragilis Strains Resistant to Meropenem-EDTA
Medina-Pascual MJ, Valdezate S, Carrasco G, Villalón P, Garrido N, Saéz-Nieto JA. (2015) Increase in isolation of Burkholderia contaminans from Spanish patients with cystic fibrosis. Clin Microbiol Infect. ;21(2):150-6.
PUBMED DOIAn increase in negative supercoiling in bacteria reveals topology-reacting gene clusters and a homeostatic response mediated by the DNA topoisomerase I gene
Ferrándiz MJ, Martín-Galiano AJ, Arnanz C, Camacho-Soguero I, Tirado-Vélez JM, de la Campa AG. 2016. Nucl Acids Res. 44:7292-7303 (2016).
PUBMED DOISpatially-restricted JAG1-Notch signaling in the human thymus provides permissive microenvironments for dendritic cell development.
Martín Gayo, E., González-García, S., García-León, M., Murcia-Ceballos, A., Alcain, J., García-Peydró, M., Allende, L., de Andrés, B., Gaspar, ML. and Toribio, ML. J.Exp.Med. (2017) 214:3361-3379
PUBMED DOICarbapenemase-producing Emergence of NDM-producing Klebsiella pneumoniae and Escherichia coli in Spain: phylogeny, resistome, virulence and plasmids encoding blaNDM-like genes as determined by WGS. aeruginosa in Spain: interregional dissemination of the high risk-clones ST175 and ST244 carrying blaVIM-2, blaVIM-1, blaIMP-8, blaVIM-20 and blaKPC-2
14. Emergence of NDM-producing Klebsiella pneumoniae and Escherichia coli in Spain: phylogeny, resistome, virulence and plasmids encoding blaNDM-like genes as determined by WGS. Autores: Pérez-Vázquez M, Sola Campoy PJ, Ortega A, Bautista V, Monzón S, Ruiz-Carrascoso G, Mingorance J, González-Barberá EM, Gimeno C, Aracil B, Sáez D, Lara N, Fernández S, González-López JJ, Campos J, Kingsley RA, Dougan G, Oteo-Iglesias J; Spanish NDM Study Group. Revista: J Antimicrob Chemother. 2019 Dec 1;74(12):3489-3496.
PUBMED DOIEpidemiology of the Acinetobacter-derived cephalosporinase, carbapenem-hydrolysing oxacillinase and metallo-beta-lactamase genes, and of common insertion sequences, in epidemic clones of Acinetobacter baumannii from Spain
Villalón P, Valdezate S, Medina-Pascual MJ, Carrasco G, Vindel A, Saez-Nieto JA. Epidemiology of the Acinetobacter-derived cephalosporinase, carbapenem-hydrolysing oxacillinase and metallo-beta-lactamase genes, and of common insertion sequences, in epidemic clones of Acinetobacter baumannii from Spain. J Antimicrob Chemother. 2013;68(3):550-3.
PUBMED DOIRapid cross-border emergence of NDM-5-producing Escherichia coli in the European Union/European Economic Area, 2012 to June 2022
15. Rapid cross-border emergence of NDM-5-producing Escherichia coli in the European Union/European Economic Area, 2012 to June 2022. Autores: Linkevicius M, Bonnin RA, Alm E, Svartström O, Apfalter P, Hartl R, Hasman H, Roer L, Räisänen K, Dortet L, Pfennigwerth N, Hans JB, Tóth Á, Buzgó L, Cormican M, Delappe N, Monaco M, Giufrè M, Hendrickx AP, Samuelsen Ø, Pöntinen AK, Caniça M, Manageiro V, Oteo-Iglesias J, Pérez-Vázquez M, Westmo K, Mäkitalo B, Palm D, Monnet DL, Kohlenberg A. Revista: Euro Surveill. 2023 May;28(19):2300209.
PUBMED DOISimian immunodeficiency virus engrafted with human immunodeficiency virus type 1 (HIV-1)-specific epitopes: replication, neutralization, and survey of HIV-1-positive plasma
Yuste E, Sanford HB, Carmody J, Bixby J, Little S, Zwick MB, Greenough T, Burton DR, Richman DD, Desrosiers RC, Johnson WE*. 2006. J Virol 80:3030-41.
PUBMED DOIThe formation of titan cells in Cryptococcus neoformans depends on the mouse strain and correlates with induction of Th2-type responses
García-Barbazán, I., Trevijano-Contador, N., Rueda, C., de Andrés, B., Pérez-Tavárez, R., Herrero-Fernández, I., Gaspar ML., and Zaragoza, O. Cellular Microbiology (2015) 18:111-124
PUBMED DOICarbapenemase-Producing Klebsiella pneumoniae From Transplanted Patients in Brazil: Phylogeny, Resistome, Virulome and Mobile Genetic Elements Harboring blaKPC-2 or blaNDM-1.
16. Carbapenemase-Producing Klebsiella pneumoniae From Transplanted Patients in Brazil: Phylogeny, Resistome, Virulome and Mobile Genetic Elements Harboring blaKPC-2 or blaNDM-1. Autores: Raro OHF, da Silva RMC, Filho EMR, Sukiennik TCT, Stadnik C, Dias CAG, Oteo Iglesias J, Pérez-Vázquez M. Revista: Front Microbiol. 2020 Jul 15;11:1563.
PUBMED DOIHigh susceptibility to zoliflodacin and conserved target (GyrB) for zoliflodacin among 1209 consecutive clinical Neisseria gonorrhoeae isolates from 25 European countries, 2018.
Unemo M, Ahlstrand J, Sánchez-Busó L, Day M, Aanensen D, Golparian D, Jacobsson S, Cole MJ, Torreblanca RA, Ásmundsdóttir LR, Balla E, De Baetselier I, Bercot B, Carannante A, Caugant D, Borrego MJ, Buder S, Cassar R, Cole M, Dam A, Eder C, Hoffmann S, Hunjak B, Jeverica S, Kirjavainen V, Maikanti-Charalambous P, Miriagou V, Mlynarczyk-Bonikowska B, Pakarna G, Patterson L, Pavlik P, Perrin M, Shepherd J, Stefanelli P, Unemo M, Jelena V, Zákoucká H. J Antimicrob Chemother. 2021 Feb 10:dkab024
PUBMED DOIDissemination of extensively drug-resistant NDM-producing Providencia stuartii in Europe linked to patients transferred from Ukraine, March 2022 to March 2023
17. Dissemination of extensively drug-resistant NDM-producing Providencia stuartii in Europe linked to patients transferred from Ukraine, March 2022 to March 2023. Autores: Witteveen S, Hans JB, Izdebski R, Hasman H, Samuelsen Ø, Dortet L, Pfeifer Y, Delappe N, Oteo-Iglesias J, Żabicka D, Cormican M, Sandfort M, Reichert F, Pöntinen AK, Fischer MA, Verkaik N, Pérez-Vazquez M, Pfennigwerth N, Hammerum AM, Hallstrøm S, Biedrzycka M, Räisänen K, Wielders CC, Urbanowicz P, de Haan A, Westmo K, Landman F, van der Heide HG, Lansu S, Zwittink RD, Notermans DW, Guzek A, Kondratiuk V, Salmanov A, Haller S, Linkevicius M, Gatermann S, Kohlenberg A, Gniadkowski M, Werner G, Hendrickx AP. Revista: Euro Surveill. 2024 Jun;29(23):2300616.
PUBMED DOICharacterization of Carbapenemase-Producing Klebsiella oxytoca in Spain, 2016-2017.
18. Characterization of Carbapenemase-Producing Klebsiella oxytoca in Spain, 2016-2017. Autores: Pérez-Vazquez M, Oteo-Iglesias J, Sola-Campoy PJ, Carrizo-Manzoni H, Bautista V, Lara N, Aracil B, Alhambra A, Martínez-Martínez L, Campos J; Spanish Antibiotic Resistance Surveillance Program Collaborating Group. Revista: Antimicrob Agents Chemother. 2019 May 24;63(6): e02529-18.
PUBMED DOIThe global meningitis genome partnership
Rodgers E, Bentley SD, Borrow R, Bratcher HB, Brisse S, Brueggemann AB, Caugant DA, Findlow J, Fox L, Glennie L, Harrison LH, Harrison OB, Heyderman RS, van Rensburg MJ, Jolley KA, Kwambana-Adams B, Ladhani S, LaForce M, Levin M, Lucidarme J, MacAlasdair N, Maclennan J, Maiden MCJ, Maynard-Smith L, Muzzi A, Oster P, Rodrigues CMC, Ronveaux O, Serino L, Smith V, van der Ende A, Vázquez J, Wang X, Yezli S, Stuart JM. J Infect. 2020; 81(4): 510-520
PUBMED DOISpread of the FAR-MRSA clone, a fusidic acid- and meticillin-resistant Staphylococcus aureus ST121, Europe, 2014 to 2024.
19. Spread of the FAR-MRSA clone, a fusidic acid- and meticillin-resistant Staphylococcus aureus ST121, Europe, 2014 to 2024. Autores: Roer L, Yin N, Denis O, Vendrik KE, Zwittink RD, Notermans DW, Perrin M, Khonyongwa K, Tristan A, Youenou B, Layer-Nicolaou F, Werner G, Enger H, Eikrem ECH, Darenberg J, Mäkitalo B, Paulsson M, Björkman J, Fang H, Hallbäck ET, Sundqvist M, Lindholm L, Moganeradj K, García-Cobos S, Cañada-García JE, Holzknecht BJ, Eriksen HB, Hoppe M, Bartels MD, Samaniego Castruita JA, Urth TR, Larsen AR, Petersen A. Revista: Euro Surveill. 2025 Jul;30(28):2500452.
DOIEpidemiology, molecular characterisation and antimicrobial susceptibility of Neisseria gonorrhoeae isolates in Madrid, Spain, in 2016
María D. Guerrero-Torres, María B. Menéndez, Carmen S. Guerras, Estela Tello, Juan Ballesteros, Petunia Clavo, Teresa Puerta, Mar Vera, Oskar Ayerdi, Juan C. Carrio, Inmaculada Monzo, Jorge del Romero, Julio A. Vázquez, Raquel Abad. 20. María D. Guerrero-Torres, María B. Menéndez, Carmen S. Guerras, Estela Tello, Juan Ballesteros, Petunia Clavo, Teresa Puerta, Mar Vera, Oskar Ayerdi, Juan C. Carrio, Inmaculada Monzo, Jorge del Romero, Julio A. Vázquez, Raquel Abad. Epidemiol Infect. 2019 Sep 24;147:e274
PUBMED DOIContent with Investigacion .
-
Óscar Zaragoza Hernández
Research Professor
ORCID code: 0000-0002-1581-0845
Dr. Oscar Zaragoza graduated in Biology from the Complutense University of Madrid in 1995 and obtained his PhD from the Autonomous University of Madrid. He completed his doctoral thesis (2000) at the CSIC under the direction of Dr. Juana María Gancedo on the topic of glucose catabolite repression in Saccharomyces cerevisiae. During this period, he was also tutored by Dr. Carlos Gancedo in collaborative projects, that allowed him to start working with the pathogenic yeast Candida albicans.
After a brief postdoctoral stay in the same laboratory, in 2001, he joined the laboratory of Dr. Arturo Casadevall (Albert Einstein College of Medicine, New York), where he specialized in research into virulence mechanisms of pathogenic fungi, mainly Cryptococcus neoformans. In 2006 he joined the National Center for Microbiology of the ISCIII thanks to a “Ramón y Cajal” contract and he became staff scientist in 2009. Currently, he occupies the rank of Research Professor of the OPIs.
During his career, he has published more than 140 articles, 4 book chapters and a popular book ("Microscopic fungi: Friends or Enemies?"). He has obtained public and private projects, and participates as CoIP of a CIBERINFEC group. He has supervised seven doctoral theses, and numerous master's thesis projects.
-
Alba Torres Cano
PhD student (FPI contract)
ORCID code: 0009-0008-3151-1803
Alba Torres Cano has a degree in Health Biology from the University of Alcalá de Henares (UAH), and completed the master's degree "Microbiology Applied to Public Health and Infectious Diseases" from the UAH. He completed his master's thesis at the CNM under the direction of Dr. Zaragoza in 2022, focusing on pathogenic yeasts. In that year, he joined the ISCIII with an FPI predoctoral contract under the direction of Dr. Óscar Zaragoza.
-
-
Alejandra Lora Plaza
PhD student (FPI contract)
ORCID code: 0009-0004-4344-1583
Alejandra Lora Plaza graduated in Health Biology and completed the Master in Applied Microbiology in Public Health and Infectious Diseases Research (2021) at the University of Alcalá in both cases. She joined the Department of Microbiology of the Faculty of Biology of the University of Barcelona to carry out her internship and her final degree work. Subsequently, she did her Master's thesis at the Microbiology Laboratory of the Hospital Universitario Príncipe de Asturias. In 2022 she joined the Public Health and Epidemiology group at the Marqués de Valdecilla Research Institute (IDIVAL), Santander, as a research support technician. In 2024 he joined Dr. Concha Gil's group in the Department of Microbiology and Parasitology at the Faculty of Pharmacy of the Complutense University of Madrid focusing on yeasts.
In 2025 she joined ISCIII with a predoctoral FPI fellowship under the direction of Dr. Óscar Zaragoza.
List of staff
Additional Information
This group, together with the CNM Serology Laboratory (LS), houses the National Reference Laboratories for Rabies (RD 1940/2004) and Measles and Rubella (National Elimination Plan) that are integrated into the corresponding European networks. It has 10 self-developed techniques in its service portfolio (2 accredited by ENAC and 3 by the WHO). In addition, it attends to three CNM microbiological surveillance programs (measles and rubella, mumps and rabies). It is integrated into a CIBERESP group of which Juan E. Echevarría is head and in which other CNM researchers participate.
Research on MMR vaccine diseases is currently financed through an AESI project (PI15CIII/00023) of which Aurora Fernández García is co-PI and in which the LS, the CNE, the CAM (LRSP and the Epidemiology Service) and a network of primary care pediatricians participate. of the CAM.
Research on lisaviruses and other viruses associated with bats is currently funded through the VIROBAT-4 project (MINECO, SAF 2017-89355-P) of which Juan E. Echevarría is PI and in which the CNM Respiratory Viruses Laboratory, the Doñana Biological Station (CSIC) and the University of Alcalá de Henares participate.
This group, together with the CNM Serology Laboratory (LS), houses the National Reference Laboratories for Rabies (RD 1940/2004) and Measles and Rubella (National Elimination Plan) that are integrated into the corresponding European networks. It has 10 self-developed techniques in its service portfolio (2 accredited by ENAC and 3 by the WHO). In addition, it attends to three CNM microbiological surveillance programs (measles and rubella, mumps and rabies). It is integrated into a CIBERESP group of which Juan E. Echevarría is head and in which other CNM researchers participate.
Research on MMR vaccine diseases is currently financed through an AESI project (PI15CIII/00023) of which Aurora Fernández García is co-PI and in which the LS, the CNE, the CAM (LRSP and the Epidemiology Service) and a network of primary care pediatricians participate. of the CAM.
Research on lisaviruses and other viruses associated with bats is currently funded through the VIROBAT-4 project (MINECO, SAF 2017-89355-P) of which Juan E. Echevarría is PI and in which the CNM Respiratory Viruses Laboratory, the Doñana Biological Station (CSIC) and the University of Alcalá de Henares participate.